AI could turn bionic eyes into smart vision for the blind

NCT ID NCT06117332

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study tests whether AI-powered software can improve the usefulness of artificial vision for people with visual prostheses (bionic eyes). The goal is to help users better understand what they see by enhancing the visual scene, similar to augmented reality. Participants will perform tasks like detecting lights, identifying shapes, and locating objects while researchers measure their responses. The aim is to develop a 'Smart Bionic Eye' that assists with real-world activities like face recognition and navigation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-powered scene understanding software for visual prostheses
What this could lead to
If successful, this could lead to a 'Smart Bionic Eye' that helps blind individuals recognize faces, navigate outdoors, read, and perform daily tasks more effectively.
What could go wrong
This is an early-stage study with a small number of participants. The AI approach may not overcome the fundamental challenges of translating electrical stimulation into clear vision, and results may not generalize to all prosthesis users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 7 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Criteria for inclusion of visual prosthesis users: * Subject must be at least 18 years of age; * Subject has been implanted with a visual prosthesis (e.g., Argus II, Orion, Cortivis) * Subject has healed from surgery and the surgeon has cleared the subject for programming; * Subject has the cognitive and communication ability to participate in the study (i.e., follow spoken directions, perform tests, and give feedback); * Subject is willing to conduct psychophysics testing up to 4-6 hours per day of testing on 3-5 consecutive days; * Subject is capable of understanding patient information materials and giving written informed consent; * Subject is able to walk unassisted. Criteria for inclusion of sighted control subjects: * Subject speaks English; * Subject must be at least 18 years of age; * Subject has visual acuity of 20/40 or better (corrected); * Subject has the cognitive and communication ability to participate in the study (i.e., follow spoken directions, perform tests, and give feedback); * Subject is capable of understanding participant information materials and giving written informed consent. * Subject is able to walk unassisted Exclusion criteria: * Visual prosthesis users: Subject is unwilling or unable to travel to testing facility for at least 3 days of testing within a one-week timeframe; * Sighted controls: Subject has a history of motion sickness or flicker vertigo * All: Subject has language or hearing impairment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blindness, acquired are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Miguel Hernandez

    Elche, Alicante, 03202, Spain

  • University of California, Santa Barbara

    Santa Barbara, California, 93106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.